Ophthalmic Business News

Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.

In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care.

The FDA cleared an investigational new drug application for OpCT-001, an investigational cell therapy for the treatment of primary photoreceptor diseases, according to a press release from BlueRock Therapeutics.

Retirement planning for physicians is a critical aspect of financial management, given the unique challenges and opportunities they face.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Cari Stone of Elios Vision previews the company’s excimer laser for the treatment of glaucoma.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Carole C. Foos, CPA, of OJM Group discusses saving and investing pearls for ophthalmologists.

The European Commission granted marketing authorization to Akantior for the treatment of Acanthamoeba keratitis, according to a press release from Avanzanite Bioscience.

Most physicians receive a regular paycheck, and sometimes receive a lump sum such as a bonus. A proportion of both should be invested. How should one invest a portion of their regular paycheck?

Icare Finland Oy, a subsidiary of Revenio Group, has signed an agreement to acquire the AI software company Thirona Retina, according to a press release.

Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.